Person:
Maertens, Ophelia

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Maertens

First Name

Ophelia

Name

Maertens, Ophelia

Filters

20121

Settings

Author's Publications: search.filters.isAuthorOfPublication.7c866590-31a8-4319-b57d-db58d20c7d06

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
    (American Association for Cancer Research (AACR), 2012) Ercan, Dalia; Xu, Chunxiao; Yanagita, Masahiko; Monast, Calixte S.; Pratilas, Christine A.; Montero, Juan; Butaney, Mohit; Shimamura, Takeshi; Sholl, Lynette; Ivanova, Elena; Tadi, Madhavi; Rogers, Andrew; Repellin, Claire; Capelletti, Marzia; Maertens, Ophelia; Goetz, Eva Marie; Letai, Anthony; Garraway, Levi; Lazzara, Matthew J.; Rosen, Neal; Gray, Nathanael; Wong, Kwok-Kin; Janne, Pasi
    The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by the EGFR T790M mutation. Here we show, in multiple complementary models, that resistance to WZ4002 develops through aberrant activation of ERK signaling caused by either an amplification of MAPK1 or by downregulation of negative regulators of ERK signaling. Inhibition of MEK or ERK restores sensitivity to WZ4002 and prevents the emergence of drug resistance. We further identify MAPK1 amplification in an erlotinib resistant EGFR mutant NSCLC patient. In addition, the WZ4002 resistant MAPK1 amplified cells also demonstrate an increase both in EGFR internalization and a decrease in sensitivity to cytotoxic chemotherapy. Our findings provide insights into mechanisms of drug resistance to EGFR kinase inhibitors and highlight rationale combination therapies that should be evaluated in clinical trials.